Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If sitting on an FDA panel tomorrow voting on whether to send PPHM Bavi back to "Go", and someone showed you the studies on all-human Bavi MAB and prostate cancer, would recent events at Peregrine Pharm. make you look more/less carefully/favorably on a proposed fully humanized Bavi trial in prostate cancer? PPHM, Inc. reputation appears to me to be no worse than before the deluge one week ago. It appears that awareness and Bavi- (anti-PS MAB) technology is blooming. Lots of people love underdogs with a compelling story...and PPHM pipeline is a good one. Bavi- will one day be in the pioneering group of Avastin and ERbitux MABs, now grudgingly retiring from the field of battle. Does PPHM's Bavi have sumpin' special? Yes. It's no threat to existing treatment methods...supplements their action by helping the body clean out the death and debris caused by chemo-, irradiation, or surgery. Has the battle against solid tumors with MABs/immunomodulators moved forward as a result of efforts at PPHM? I think so.
CJ and learningcurve: thank you for all the time you donated in clarifying and teaching aboutK-M curves. What is your "gut" analysis after such long and careful inspection in this PII Bavi trial? I'm curious to see if it the same as mine. Cheers, and thanks again. Great week-end discussion
Bungler, a nonsequiter: you nailed it.
PPHM has FULLY Humanized Bavi in the wings. Also, PPHM has a better Avastin MAB in human trials in Russia. PPHM Cotara MAb HAS demonstrated superior survival to SOC in worst brain cancer, glioblastoma multiforme. We'll be visiting several PPHM pipeline items lest you think Bavi is PPHM sole winner:
Classic CJGaddy post; April 22, 2009
“Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody [PGN635, aka 1N11] in Prostate Cancer Model.
• Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform
• Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%”
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=378985
DENVER & TUSTIN, April 22, 2009: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that preclinical data presented during the AACR 100th Annual Meeting 2009 shows that one of its fully human phosphatidylserine (PS)-targeting antibodies demonstrated encouraging signs of efficacy in a preclinical model of prostate cancer. These positive new data validate the anti-tumor potential of this human anti-PS antibody, which is similar to Peregrine's lead clinical stage antibody bavituximab and extends Peregrine's anti-PS antibody pipeline. Bavituximab is in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.
Peregrine's PS-targeting antibodies bind to the cellular membrane component PS that is usually located inside cells, but which becomes exposed on the external surface of the cells that line the blood vessels of tumors (the tumor vascular endothelium), creating a specific target for anti-cancer treatments. By binding to PS, the antibodies are believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels.
In today's presentation, researchers from UT Southwestern Medical Center in Dallas and Affitech A/S reported that similar to bavituximab, the human antibody PGN635 [aka 1N11] targets and binds specifically to the tumor vascular endothelium(1). Treatment with androgen deprivation therapy or docetaxel substantially increased the percentage of tumor blood vessels with PGN635 binding.
The researchers also reported that in a mouse model of prostate cancer, treatment with a mouse-equivalent antibody of PGN635 significantly retarded the growth of tumors by more than 90%. These positive results reinforce the findings of previous preclinical studies with Peregrine's anti-PS antibodies that showed promising anti-tumor activity in combination regimens in models of prostate cancer.
"As our understanding of PS-targeting antibodies continues to increase, the availability of anti-PS antibodies that vary in their mode of binding or in their specific immunomodulatory activity broadens the potential clinical applications of our anti-PS technology platform," said Steven W. King, president and CEO of Peregrine. "Our collaboration with Affitech to generate fully human anti-PS antibodies has produced a number of antibodies with varying characteristics. We look forward to continuing to pursue both internal efforts and external collaborations to further explore the clinical potential of these promising development candidates."
The fully human PS-targeting antibody in this study was developed through Peregrine's collaboration with Affitech A/S. The studies were supported in part by a grant and a post-doctoral fellowship from the U.S. Department of Defense.
Peregrine's lead PS-targeting antibody bavituximab is currently in 2 separate Phase II combination therapy trials for the treatment of advanced breast cancer, one in combination with docetaxel and the other in combination with carboplatin & paclitaxel. A third Phase II trial in combination with carboplatin & paclitaxel is currently ongoing for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.
(1) Yi Yin, Anita Kavlie, Philip E. Thorpe. UTSW-MC/Dallas, Affitech AS, Oslo, Norway.
“Fully human anti-phosphatidylserine antibody inhibits the growth of prostate cancer in mice”
In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia
AACR; 2009. Abstract nr 5463
ABOUT PEREGRINE PHARMACEUTICALS
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing 3 separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Safe Harbor *snip*
Contacts: GendeLLindheim BioCom Partners
Investors: 800-987-8256, info@peregrineinc.com
Media: Barbara Lindheim, 212-918-4650
*end*
= = = = = = = = = AACR’09 4-20-09:
#5463: Fully-Human Anti-PS 1N11=PGN635 “Inhibits the Growth of Prostate Cancer in Mice”
AACR 2009 Abstract #5463 4-22-09 8am-12pm http://tinyurl.com/cqv9az
Poster Session: Antibody Technologies
”Fully Human Anti-Phosphatidylserine Antibody [1N11=PGN635] Inhibits the Growth of Prostate Cancer in Mice”
Yi Yin, Anita Kavlie [Senior Scientist, Affitech], Philip E. Thorpe
UTSW-MC/Dallas, Affitech AS, Oslo, Norway
ABSTRACT: Phosphatidylserine (PS), a phospholipid normally residing in the inside leaflet of the plasma membrane, becomes exposed on tumor vascular endothelial cells in response to oxidative stresses in the tumor microenvironment. Anti-PS antibodies have been developed. Binding of anti-PS antibodies on the tumor endothelial cells recruits immune cells to destroy tumor vasculature. The antibodies also enhance anti-tumor immunity by blocking the immunosuppressive action of PS. A chimeric anti-PS antibody, bavituximab, is being used in combination with chemotherapy to treat patients with metastatic breast cancer in Phase II trials. We developed the fully human anti-PS antibody 1N11 [aka PGN635 = Fully-Human Bavituximab]. Being fully human, 1N11 is less likely to evoke an anti-antibody response in clinic. The antibody was tested for cross reactivity profiles by ELISA, and its ability to localize to tumor vessels by immunofluoresence staining. 1N11 binds to PS through beta-2-glycoprotein 1 (B2GP1) in the same manner as bavituximab. It recognizes human and mouse B2GP1 with equal affinity, whereas bavituximab is selective for human B2GP1. 1N11 localized specifically to tumor vascular endothelium after injection into severe combined immunodeficient mice bearing LNCaP and PC3 tumors. Treatment with castration increased the percentage of tumor vessels with 1N11 binding from 20% to 80% in mice bearing LNCaP xenografts. Treatment with docetaxel increased the localization of 1N11 on tumor vessels from 30 to 65% in mice bearing PC3 xenografts. To evaluate therapeutic efficacy of 1N11, we created a mouse IgG2a chimeric version, called mch1N11, to ensure compatibility with mouse effector cells and complement. Treatment with mch1N11 retarded the growth of orthotopic PC3 tumors by more than 90% as judged by bioluminescent imaging. Toxicity to the mice was not observed. These results provide the rationale for using 1N11 alone, or in combination with androgen deprivation therapy or chemotherapy to treat prostate cancer patients.
= = = = = = = BACKGROUND ON 1N11=PGN635=FH-BAVI:
10-23-08 Affitech’s Dr. Anita Kavlie presents 1N11/PGN635(FH-Bavi) & R84/PGN311(2C3) at ANTIBODIES-EUR’08: http://tinyurl.com/4w9qba
4-15-08: AACR2008 #4079, Bavi/PGN635(fully-human) Induces ADCC http://tinyurl.com/6ql5nf
…Steven King, ”by blocking PS and its anti-inflammatory signals, our anti-PS antibodies unleash powerful pro-inflammatory effects that enhance their anti-cancer effectiveness.”
...5-6-08 Affitech's followup PR on PGN635: http://tinyurl.com/3h26wk
= = = = = = = = = = =
###THREE DOD GRANTS TO THORPE/MASON (UTSW) FOR BAVI/AC PRE-CLINICAL STUDIES:
4-25-06 3rd DOD Grant W81XWH-06-1-0475: $460k, Mason, Bavi+Rad vs. Breast Cancer http://tinyurl.com/v9hye
Dr. Mason: "Since bavituximab's unique target is expressed on blood vessels in tumors but not in normal tissues, it may have both safety & efficacy advantages compared to other antibodies. We are eager to assess the utility of a bavituximab radioimmunoconjugate for the identification and treatment of metastatic breast disease." CEO S.King, "Data from this project could open the door for use of Bavituximab as an agent to identity, measure and ultimately destroy the metastases that kill most cancer patients."
...Dr. Mason’s 6-2008 Bavi+Rad poster at DOD ‘Era of Hope’ Meeting (1-pg PDF): http://tinyurl.com/5e9r37
...3-1-08 Thorpe/Mason C.C.R. (AACR) article on Arsenic-labeled Bavi for Imaging: http://tinyurl.com/32jbfl
...Dr. Mason’s 4-2007 Ann.Rept #1 (18pg PDF) for DOD Grant3: http://tinyurl.com/2jz3rp
...Dr. Mason’s 8-2006 poster at SMI-2006, “Optical Imaging of Exposed PS” (1-pg PDF): http://tinyurl.com/ys2afj
...Dr. Ralph Mason's 2-2006 Lecture Video w/6 mins. on Bavi: http://tinyurl.com/yqxngq
1-18-06 2nd DOD Grant W81XWH-06-1-0149: $585k, Mason, Bavi+Chemo vs. Prostate Cancer http://tinyurl.com/y683vn
Dr. Mason: "This new prostate cancer grant, which brings together the expertise of several disciplines at UT-SW, will employ advanced techniques such as MRI tumor oximetry to measure dynamic changes in the tumors. We expect that the findings of these studies will be directly applicable to the design of Tarvacin clin. trials for prostate cancer."
...Dr. Mason’s 12-2007 Ann.Rept #2 (23pg PDF) for DOD Grant2: http://tinyurl.com/3j9y6u
...Dr. Mason’s 1-2007 Ann.Rept #1 (16pg PDF) for DOD Grant2: http://tinyurl.com/2jz3rp
...Dr. Mason’s 9-2007 poster (PDF) at DOD/IMPACT Conf: http://tinyurl.com/2mql39 & http://tinyurl.com/2jalhs
11-3-05 1st DOD Grant PC050301: $583k, Thorpe, Bavi+Chemo vs. Prostate Cancer http://tinyurl.com/wcwl7
Dr. Thorpe: "This DOD grant will enable us to further investigate current evidence that Bavi in combo with chemo strongly inhibits tumor growth in pre-clin. models of prostate cancer. Receipt of this peer-reviewed DOD grant signals the growing scientific interest & acceptance of the potential therapeutic value of our VTAs"
dawg, I was only "in and out" of DNDN. In late. Out too early on FDA initial action. Won't do that again! FDA is learning just like we are. The MAB/immunology field is the current vogue since DNA "dark matter" seems momentarily unmanageable. I'll opt for MAB genetic engineering for the near future.
dawginlife, agree that FDA will act correctly on this as they usually do. If the FDA overshoots it seems to be in the direction of supporting new avowed cures rather than the opposite. The FDA wants to move the ball forward also, and we all know the side-effect profile trumps all but efficacy. Even slight efficacy indications in "far-gone" cases would imply a responsibility to allow continued human trials, and wider use of Bavi. That said, it would not be surprised to see some...uhh...damping or tamping down of the somewhat exuberant numbers reported. If it's too good to be true... Garnick had never seen anything like it...Gazillions! Oversell. REpeat...if you've been in the eye of a new storm-force for good, and for making money, you understand the aggressive forces brought to bear here.
jakedogman, really. The FDA is looking for safety and efficacy. We know Bavi is safe. MOS data, although, as we've discovered, not perfect, is nonetheless compelling. If it doesn't hurt and it possibly-probably helps, how foolish can the "deciders of society" be to turn their back on the evidence and say, "next". At this point the accumulation of data had been relatively smooth, and PPHM did not put one foot wrong. Have they yet? I really not think the company has purposely or materially distorted the data it has received. It is possibe a third party did. A glance at PPHM's pipeline and AVID MAB production facility tells me we're still in good shape.
exwannabe, nice. Censor issues may, in fact, loom large in this crisis. "Staging" of the cancer for size type, primary site, and metastasis may lag or creep depending on technology, training,etc. Bavi effective? That postulate will probably be inferred from PII trial data FDA scientists are intelligent and insightful, and MUST respond in the public interest. Bavi side-effect profile in lower animals and humans is extensive, and safe.
Its rationale, superb. There are several MD posters here, and that is because the company has not hyped its product, its administration has been forthright, its scientists brill and ethical, The intellectual community behind PPHM? Internationally known to be one of the best: UTSW. The lawsuits and the stock gyrations pale in cost and value compared with the value, of which we saw a glimmer last week. I've said for years that the price will go up when all the financial interests are aligned.
I was on the ground floor of another breathtaking breakthrough in clinical medicine, and know firsthand how greed rushes in when it appears that relative unknows are truly onto something great. Cheers!
dia, nice post. thanks.
The one over-riding consideration here is what does the company and any sub rosa sponsor (as before) now know about Bavituximab effects on cancer that we don't know. All this legal/financial buzz is interesting, but I would be willing to bet as much as I lost last week that someone knows one heck of a lot more about Bavi NOW about months of survival with or without. Virtually every possible error can be mathematically modeled and odds calculated. Bavi and no Doce. Doce +Bavi, yada. I'll say it again. Do the math. This is not rocket science. We are back to exactly where we were a few weeks ago with the stock price-wise, and NOT where we should be with the knowledge which has been accrued. Does a simple answer to these questions seem possible at this point? "It looks like Bavi works. It doesn't look like Bavi works. We still have no clue whether Bavi works." Let's stay focused. Somebody DOES know, and that somebody was buying big.
jake, censoring issues in patient test populations are a phenom. with which everyone is familiar. Without a full-page narrative, I will compare a rare call on a censored patient to be similar to the goal-line call in the GBPacker game. There are going to be close calls. Overall, the stats should speak for themselves. Again, either more patients lived longerthan the placebo or they didn't.
cloaked, fab. thanks. Paranoid as I am, the sabateur scenario is rather low on my list. Must admit that what flashed through my mind was many a day/night in the lab labeling tubes, and having racks of tubes with labels on them only to find that the contents don't synch up with the labels, yada. What to do?! Dishonesty, maybe. Laziness, probably. Culpability? The "third party" execs. on their cruisers, or the minimum wage labby trying to meet a deadline and looking at jangled labels. We'll see.
techwriter, good post. you're the man...
immunidose, why so bleak? "darker before dawn?!" The FDA is not going to drag its feet or drag anything else if the numbers show statistically significant survival in one or both or pooled treatment groups. We're all here (and there) trying to apply the rule of reason to reconstructing a shipwreck caused in part by a faulty fathometer when all brass on board were "blinded" by the dark. I imagine the FDA has vetted the 3rd party at fault. It's at least partly their problem, not all PPHM's. Today's market results tend to reinforce (the usual) overshoot in the downside yesterday, and the early morning tide appears to have lifted good ship PPHM off the shoals. Patches being applied...
Reminder. This board is going to be scrutinized like no other...ever...starting last Friday. For the sake of exchanging information some OffTopic posts not consistent with purpose will necessarily be deleted to facilitate exchange of ideas and info. You have raised the "SOC" in messageboarding to a great new level. You "trapped" longs, welcome. PPHM remains in a good place IMO, having doubled in the past few weeks. Nothing has changed about product efficacy. Start with today...again.
DO THE MATH Simple, really. We know what SOC average overal survival is in MANY thousands of patients. No question that average survival with NSCLC is about 7.2mo. Bavi and SOC are mixed in three treatment groups...possibly randomly. The PII Bavi trial has become a multi-dose asynchronously delivered Bavi + SOC. Did the SOC group + placebo follow the usual course, or did that group show abnormal survival, indicating that the dread Bavi seeped into the control group as well. Mathematically, it seems correct. The question therefore devolves to whether the overall group showed significant improved survival. I think we lucked out. The next logical move by FDA would be to split the difference between 1mg and 3mg....Launch at 2mg, and study 1mg and 3mg if it comes to that. Let's keep the ball moving. You got a glimpse of the big leagues. Gonna get sent packing? the big leagues. "Noisers" is a new term, and Noisemakers are louder here than ever. Deeply imbedded double agents. Big dollars. Experienced actors. All the elements...
loof, sorry to see you cash out, but if memory serves, it isn't the first time. Right? All the articles and posts here about loss of confidence can apply to those who don't understand the science, and do not have a sense of what the corporate officers have done in the past, but I will repeat: IMO they have always acted in the most ethical manner possible. Remember, the CEO is an MD. The most signicant thing about that, perhaps, is that we are all painfully aware of another CEO MD, Sam Waxsal, of ImClone who, along with Martha Stewart, both did hard time for insider trading and similar, and with all the pain criminal trial and conviction brings with it, we are all conscious of consequences which will not lessen as time goes on. On Friday I wrote that it was a time to inventory possible loose ends that could defeat us when victory seemed at hand; that PPHM remained speculative; that Bavi is not a cure, but will probably find a place on the treatment table as an adjunct; that I would take it, and I would prescribe it (still, now). It is a legal world, and sadly, I find that physicians (as an example) cannot always say comforting words to those in mourning because of the possible legal ramifications of ANYthing they might say. On one hand I am upset that every large institutional holder had access to the sell lever before mom and pop retailer. However, I was locked and loaded for a purchase at the opening, and the timing saved me and a lot of others a huge amount of money. And Loof, I know it's no consolation, but my loss of unrealized gains today was in the neighborhood of $1/2 million. That said, I will be buying this afternoon. Best wishes to all. Hang in. I said the $5 pivot was a beatch, but had no idea.....PS. I'll be at the SHM too...for dinner the night before.
great post cloaked protector. best of the 100+ already today.
am I selling? no. wishing I sold Friday? yes. buying? thinking seriously about it. $5 turned out to be quite a pivot point at that. I was going to jump in big this morning. Had been holding back lately because of how much more a thousand shares cost than three month ago. Wishing I'd bought more when it was in the $1 range. Another infamous PPHM buying opportunity! We all got a brief taste of "the wealth effect" created by an up market.
The company owes stockholders an immediate explanation in terms that everyone can understand about exactly what the problem is, and what the potential ramifications are. The press release tells me nothing about the problem details. Did the control arm get Bavi? Did the Bavi arm get placebo? How many trial sites? All/some? Basic statistical savvy would alert management to a problem if one or two sites were outlyers. Or were the groups not properly stratified by severity of disease. And, as a couple here have asked, what about the patients who are living longer who didn't know which they were/are getting? Most likely, nobody knows for certain who got which, placebo or Bavi, and the trial will have to be run again. The incredible 800 pound gorilla in the room is not the glitch but the patients who are survivers to date. If nothing else we need to know if these are patients with less severe disease going into the trial, and I doubt that is the case. If the glitch only involves this one trial we will soon have some information on pancreas and liver trials. Wow, just when past credibility issues were being forgotten. Stuff happens. This does not appear to be a reflection on PPHM ethic, but rather on choice of the company charged with encrypting and tracking the blinded protocol in the clinical trial. Amazing.
volgoat, what nobody has said (today, that is) that almost certainly a big pharma that is current in the picture has probably been in the background all along to prop up the science and trod on the stock price. As noted ad infinitum, the old saying about the value of a company at any moment in time is the stock price is just plain stupid. Those of us who have seen the elegant animal trials, the theories being borne out in the lab, and then mirrored in human trials feel pretty comfortable about "the results of only one PII trial". That said, I agree that a buyout is not likely; that a lot more ups and downs are in our future because the vultures are becoming more sophisticated, not less; that there remains considerable speculation; and that to look at Bavi as a cancer "cure"is amost certainly wrongheaded. However, for all the reasons listed above, there are many of us who look forward to the day Bavi can be used on a preventive, or very early intervention. NOW we're talking.
drragmop, you said that the 10x gain in the past three months is a "loose foundation" to build on, which has some validity on its face, but I think those of use who have been on board a decade or longer are very comfortable with the technological foundation on which that gain is built. The elegance and thoroughness of the laboratory work, animal trials, and, finally, human trials is nothing short of awesome from a scientific POV. The fact that the company STOCK has been (and will continue to be) gnawed to pieces repeatedly by scavengers bent on beating it down really does not relate to the stability of the base or platform. This isn't a couple kids in a vacant field shooting off a homemade rocket. PPHM has chops AND legs..starting in the warrens of the pharmacology department at UCSW to the upper echelons of that university. We can backfill gaps and worry about triple witching days and management skills, yada, ad nauseum. I continue to bank on the science. In the end its the science that will continue to sell the stock.
vanessapu and mushroom cap (and other prior lurkers) welcome.
Vanessa you have my vote to negotiate for us. Interesting ideas.
threes, great recap on Cotara. flyingfurther, yeah, there appears to be a strategic seachange (riptide?) at $5. Thanks for the beach caution sign re. playing on margin.
Threes, didn't see here where any poster argued that PPHM was slowing Cotara development. Bavi is so enormous that it is understandable that it has been backburnered. The reality is that China is carrying the ball with Cotara, and as mentioned earlier, China seems past due to shout or get off the pot about Cotara. Did it simply disappear down an Asian disclosure black hole. Or is China about to make an announcement too. Bavi is such a winner to the financial community because of the absolute manopoly at PPHM in cooking the MAB recipe to FDA standards. Speaking of China, they are supposed to have mega-MAB facilities coming online in the near future. Any update on that?
2ndstr2thert. you've been around to remember VEA? Lurking? Wasn't that given by PPHM to MerckGermany to develop? That's like giving a henhouse to a fox to "develop". A manufacturer of chemotoxins which are used for cancer would probably want control of a VEA that decreases the therapeutic dose of chemotoxin by 1/2, and then by 1/2 again. Not sure about VEA. Anyone?
stoneroad said, the road to $100 has begun...Reminds me of ImClone days when I got in at $17, and rode it to $100. LOTS of miles to travel here, with myriad greedies swoopin' in to wrest your goodies from you. PPHM has two orders of magnitude greater assets than did ImCl (100 x). Bavi is the perfect retail product: no competition and no threat to existing competition. Welcome to the playing field Bavi! You make everyone look better...from the halls of the FDA to the coridors of UTSW...to yes,even PPHM stockholders.
smartTrader, Nitwit isn't the first short who posts here, who has "turned"...and turned in short order...to a long. Nitwit is a smart guy too.
flyingfurther, amen. PPHM's attention to membrane phospho-lipids is groundbreaking, and the human trials fascinating in light of the effects on anti-cancer, anti-viral, anti-parasitic, basic immunology, apoptosis, and the Anti-PS Syndrome, to scratch the surface. Anti-phospholipid tech. is indeedd a geni jugful of interesting genetically-engineered joy. You mentioned anti-PE (phosphytidylethanoleamine sp?), and there are so many more of them. Simply understanding their role, and having secondary docking sites to design for and launch MABs at... will occupy investigators for years. With Bavi- PPHM is, simply-stating, advancing an entire new technology, and (as in many other cases of unintended consequences)the spinoffs in other fields of non-malignant disease and imaging, to mention only two, will be fab.
goodhuntingjohn:good to hear. The answer to your anguish almost certainly lies in China where Cotara has been licensed for lung cancer for several years and lingers...and nary a murmur from the Oblique Dynasty in that regard. However, even that regime is anxious for glory, and could hardly withstand the negPR of withholding life-saving biotech, so there must be a problem. But it's one that I am certain has a solution....once Thorpe has another 1/2-brain more or so, and wraps it around the problem. Wouldn't it be strange if much of the current whirlwind is related to Cotara results in China? If SaudiArabia can buy an election, China could buy PPHM...and probably for a song. Interesting stuff.
Bungler,the most interesting thing about PPHM pipeline is how their treatments are complementary, if its to large for Bavi, hitit with cotara,2C3, or small-molecule cytotoxin tTF which can be carried on Cotara- or Bavi-like MAB missile constructs. Cotara has been around long enough to have a very defined action and side-effect profile, and technology can deal with those. The advantage of delivering cytotoxins SPECIFICALLY to large cancer cores, the center of tumor, is obvious, and can be done. In the meanwhile, if CotaraMAB is too large to pass through the blood brain barrier, it probably won't back-diffuse through it either, so PPHM has completed PII Cotara trials for brain Cancer, and awaits funding of this near-lock PIII MAB, delivered into the spinal fluid and directly into GBM tumor. In this case the delivery system (intrathecal catheter) is probably as important as the cytotoxin. The one stumbling block with Cotara GBM trials is that double-blinded studies have not been done, and perhaps cannot be done via catheter into bulk of brain tumor mass. PPHM has a near-embarrassment of riches. Stockholders need to know just how much value is there...and not let new money steal the technology. Gawd! Then there is Avid, PPHM's own FDA-approved MAB production facility capapble of boutique orders from other biotech and large scale production of.... Looks like it is Bavi first.
kaddy,nice. nitwit:enjoy your perspective too. thanks
We've all had fun. Let's settle in at least a bit. Lots of folks are going to want to support this effort if we continue to inform. Let's dedicate this weekend to 1)kicking back; and 2)putting forth information here about PPHM that helps move the ball toward the goalline. There are a few true asskickin' stablemates to Bavi- at PPHM. Anyone remember the small molecule killer truncated tissue factor tTF? How about PPHM's 2C3, its "betterAvastin" in clinical trials in Russia. Mentioned Cotara, the I131-bearing MAB that has already established the best track record ever for survival in "the beast"...brain cancer...glioblastomamultiforme. Hello? The best treatment results to date. I think....! Someone here please set me straight on the GBM trials with Cotara. Thanks
Bungler,you've been around. At this moment rocketship PPHM is going up straight line: 12:53 PST, seven minutes to the close. Is this "trottle up"? "All engine firing wide open"?
Time for systems sweep now that we're accustomed to the, uh, rarified air, and the eyes of a wider public. Settle in guys. Reality check. BavituxiMAB, as is, appears to be a winner in combination with other cancer treatment modalities: chemo, irradiation, and surgery. can you imagine, I'm in PPHM for another product: Cotara, an admittedly antiquated missile chassis, but a dynamite concept. Cotara is a MAB that carries radioactive iodine directly to solid cancers..to their cores..to that necrotic central zone which hosts resistant "sleeper" cells, and bombs central cancer core with I131, an ancient and time-tested thyroid cancer killer. There more PPHM goodies. Maybe we could focus on those while we await the numbers. Fabulous times, these. A true game changer. Have a great weekend all!
DoWeOweFTMdinner at SHM? CJcan afford2go now2 Dinner4tw?.
magicatlast, I laughed aloud. ditto! Green at last!
smells like a new Roche motel in Tustin...eom
lanoosk, you're right. I like "tenured investors" here..eom
mahoney,si,si. 13390 Jamboree Road, Irvine, CA location of Buca ie Beppo. Closest one to PPHM and about 6 miles away from Hotel Terrace Drive (many hotels) and about 2 miles from Peregrine Headquarters. Anyone with 100k+ shares to vote gets to buy? Or at least provide the entertainment.
Mahoney and Dukesboy, Have reservations for 12-20+ people at Buca di Beppo at 7:30 Wednesday evening under "ENTDOC". That was the only practical time I could get. They DO have a bar, and don't require any up front money we can be pretty loose about arrangements. I'm not in love with Buca. Never been there. Anywhere is fine.